Key result
Capecitabine successfully replaced 5-fluorouracil without recurrence of cardiac symptoms in a patient who developed 5-fluorouracil-induced chest pain.
Why the study?
Does capecitabine prevent recurrence of cardiac symptoms in patients with 5-fluorouracil-induced cardiotoxicity?
Case Report (n=1)
Does capecitabine prevent recurrence of cardiac symptoms in patients with 5-fluorouracil-induced cardiotoxicity?
Capecitabine may be a viable and safe alternative for patients who develop 5-fluorouracil-induced chest pain, though larger trials are needed.
Answers are grounded in this paper and cite their sources.
May support capecitabine substitution after 5-FU cardiotoxicity; leaves open prospective validation before practice change.
5-fluorouracil is a chemotherapeutic agent that plays an important role in the treatment of various cancers including head and neck and gastrointestinal malignancies. Therapy with 5-fluorouracil is rarely associated with cardiotoxic effects including angina, heart failure, myocardial infarction and cardiac arrest, resulting in discontinuation at the expense of sub-optimal treatment of the targeted malignancy. In this article, we review the literature reported on 5-fluorouracil-associated cardiotoxicity and present a case of a patient who experienced chest pain on 5-fluorouracil. The cardiac symptoms subsided after initiation of capecitabine, the oral formulation of 5-fluorouracil. To our knowledge, this is only the second reported case where 5-fluorouracil was successfully replaced by capecitabine without recurrence of cardiac symptoms. Capecitabine may be a viable option for patients who develop 5-fluorouracil-induced chest pain. However, large clinical trials are warranted to confirm these findings. Currently, there is insufficient evidence to recommend an optimal approach for safe and effective alternative treatment for patients who experience 5-fluorouracil-induced cardiac adverse events.
No takes yet. Share an insight, caveat, or question.
Saneeymehri et al. (2015) conducted a case report in 5-fluorouracil-induced cardiotoxicity (n=1). Capecitabine vs. 5-fluorouracil was evaluated on Recurrence of cardiac symptoms. Capecitabine successfully replaced 5-fluorouracil without recurrence of cardiac symptoms in a patient who developed 5-fluorouracil-induced chest pain.
Synapse has enriched 10 related papers. Consider them for comparative context: